Reductions in JAK2V617F allele burden with ruxolitinib treatment in COMFORT-II, a phase III study comparing the safety and efficacy of ruxolitinib to best available therapy (BAT).
Alessandro M. Vannucchi
Consultant or Advisory Role - Italfarmaco; Italfarmaco; Novartis; Novartis
Honoraria - Italfarmaco; Italfarmaco; Novartis; Novartis
Jean-Jacques Kiladjian
Research Funding - Celgene; Novartis; Shire
Heinz Gisslinger
No relevant relationships to disclose
Francesco Passamonti
Consultant or Advisory Role - Celgene; Novartis; Sanofi
Haifa Kathrin Al-Ali
Honoraria - Novartis
Research Funding - Novartis
L. Andres Sirulnik
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Viktoriya Stalbovskaya
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Matthew Squires
Employment or Leadership Position - Novartis
Deborah S. Hunter
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Timothy Burn
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Laurent Knoops
Consultant or Advisory Role - Novartis
Expert Testimony - Novartis
Francisco Cervantes
Consultant or Advisory Role - Novartis
Tiziano Barbui
No relevant relationships to disclose
Giovanni Barosi
No relevant relationships to disclose
Claire N Harrison
Consultant or Advisory Role - Celgene; Celgene; Novartis; Novartis; S Bio; Sanofi ; YM BioSciences; YM BioSciences
Honoraria - Celgene; Celgene; Novartis; Novartis; S Bio; Sanofi ; Sanofi ; SBio; YM BioSciences; YM BioSciences
Research Funding - Novartis; Novartis
Expert Testimony - SBio; SBio